JS PD KB

PPMI Study Documentation / Operations Manuals overlap, Other PPMI Program Protocols, Data and Biospecimen Use Agreements and Policies, LBD (Aria 2020 #2728) sub-study, Innovative Medicines Initiative (CSF Acoustic Kit / Olink / Complement Luminex / Somalogic SomaScan 7K), EUbOPEN, PD BRAC access flow (NINDS BioSEND / Harvard Biomarkers Study / MJFF Cohorts BioFIND / DATATOP / FS-ZONE / LRRK2 / SURE-PD), MJFF Grant Portal opener (MJFF-019845 MC1 PET)

5 min read

PPMI Study Documentation / Operations Manuals overlap, Other PPMI Program Protocols, Data and Biospecimen Use Agreements and Policies, LBD (Aria 2020 #2728) sub-study, Innovative Medicines Initiative (CSF Acoustic Kit / Olink / Complement Luminex / Somalogic SomaScan 7K), EUbOPEN, PD BRAC access flow (NINDS BioSEND / Harvard Biomarkers Study / MJFF Cohorts BioFIND / DATATOP / FS-ZONE / LRRK2 / SURE-PD), MJFF Grant Portal opener (MJFF-019845 MC1 PET)

Data and Biospecimen Use Agreements and Policies

Primary contentNotesArchived prior version
Data Use AgreementArchive
Biospecimen Use AgreementArchive
Publications PolicyArchive
Cell Line AgreementArchive
Cell Lines Material Transfer AgreementArchive

Sub-Studies

For documents related to sub studies, go to the Sub Studies page.

Inclusion Criteria: Genetically DLB+PDD;
Existence are/ear of dementia.
Pathological diagnosis of Dementia with Lewy bodies (defined by McKeith consensus criteria, (McKeith, 2005 #2729) OR
Clinically diagnosed probable Dementia with Lewy bodies (defined by McKeith consensus criteria, (McKeith, 2005 #2729) OR
Clinically diagnosed probable Parkinson’s disease dementia (defined by Emre consensus criteria)

Exclusion Criteria:

Concurrent other neurological conditions, such as stroke, severe cerebrovascular disease or systemic disorders that could mimic Lewy body dementia or affect the interpretation of the study.

Non-European ancestry

Protocol: (Aria, 2020 #2728): 2,981 LBD cases, 2,173 neurologically healthy controls.

LBD (Lewy Body Dementia)

https://amp-pd.org/unified-cohorts/lbd/study-overview

Innovative Medicines Initiative

20240410

I’m happy to share the progress achieved by WP5 in data generation.

From the core CS1-2 cohort (N=383; AD, PD, DLB) including individuals selected from UNIGE-DZNE-UNILU-VUMC-Georgian-FACE-Motol University Hospital cohorts, WP4 has successfully completed the initial data harmonization, with only a few DLB cases outstanding. This effort has made a substantial volume of clinical variables available for analysis.

Simultaneously, partners from CS1 and CS2 have conducted a diverse array of analyses on plasma and CSF samples.

  • Roche Neurotool Kit Assay:
    CSF assays: AB40, NfL, GFAP, sTREM2, YKL40, IL-6, S100b, α-Synuclein, Neurogranin, SNAP25, NPTX2, AB42, tTau, pTau181;
    Plasma assays: AB40, AB42, NfL, GFAP, sTREM2, YKL40, S100b, α-Synuclein, Neurogranin, SNAP25, NPTX2, GFBP7, NfL, pTau181, AB(40-Y)4-, S100b, GDF-15, NSE
  • Olink Assay on CSF:
    Utilizing the O-link EXPLORE 3072 platform across eight unique panels, including cardiometabolic ( & II, inflammation I & II, neurology I & II, and oncology I & II
  • Complement Luminex Assay in CSF
    Analyzing C1q, C2, C3, C3b, C4b, C4c, C5, C5a, CS, CR, Factor I, Factor D, Factor H, Factor B, Properdin
  • Somalogic Assay in CSF
    Leveraging the SomaScan 7K platform, profiling over 7000 proteins.

The samples are still on board to embark on data analysis.

Should you wish to market data for analysis, please complete the attached form. This will enable us to reference ongoing analyses and prevent any potential overlap.

The same form will serve for future data requests within the scope of WP5 case studies analysis, and it’s conveniently accessible via SharePoint here.

In addition, you can track the progress of remaining analyses via the Excel file in share point.

Your request will be forwarded to UM, our central repository for data and clinical variables, that will provide you with the requested metadata.

Furthermore, you will receive an invitation email for our upcoming WP5 meeting, during which we will discuss the data analysis plan. Matt Clement will also be providing a brief presentation, offering insights into the capabilities of AD-workbench for data processing.

https://co-mr.eu/aria.eu/projects-results/project-factsheets/eubopen

EUbOPEN consortium / Innovative Medicines Initiative

The EUbOPEN consortium is an Innovative Medicines Initiative (IMI) funded project. The project has 22 partners from academia and industry (see below). EUbOPEN will run for five years and will have a total budget of €5.8 million euros covered by a grant from the IMI and cash and in-kind contributions from the EFPIA companies. IMI Associated Partners and non-EU partners. https://www.imi.europa.eu/projects-results/project-factsheets/eubopen

The goal of EUbOPEN is to develop high quality chemical tool compounds for 1 000 human proteins. This represents around the third of the ‘druggable’ proteins in the human body. The project will lead to the discovery of new modes of action of immunology, oncology and neuroscience.

(Takeda) Under this, their tissue assay establishment. I am now arranging a follow-up meeting with MJH

Parkinson’s Disease Biospecimen Review Access Committee (PD BRAC)

https://pdbp.ninds.nih.gov / username: freedonder pw: Annsfreed524! (oid case): Annsfreed524!, Annsfreed524!

[email protected]

PDBP, NINDS, BioSEND — [email protected]
Harvard Biomarkers Study — [email protected]
MJFF Cohorts: BioFIND, DATATOP, FS-ZONE, LRRK2 Cohort Consortium, 24-Hour BioFluid Sampling Study, SURE-PD, SURE-PD3, Niloc-PD, SURE-CORE — Email: [email protected]
For BioFIND email: [email protected]

Step 1: Determine Sample Availability: 3 category

Step 2: Submit Online Application (All applications are submitted through an online webform.)

Step 3: PD BRAC Reviews Application

PD BRAC: For access to samples from the PDBP Biorepository, Investigators must first apply for a PDBP Data Management Resource (DMR) account to query the sample availability. Once an account is obtained, biosample information can be found in the NINDS Biorepository PDBP Sample Catalog within the Query module. For assistance with DMR accounts or PDBP biosamples, please contact the PDBP Operations Team ([email protected])

Outcome Measures

Pre-Proposals Due: October 22, 2020, 5 p.m. US ET (completed submission of the proposal to MJFF on Oct 21)

MJFF’s Grant Portal: Contact [email protected] : grants.michaeljfox.org (구 https://mjff.smartsimple.com) 내 account: 원래 [email protected] AY52$ — 근데 Adam 때문에 다음 account 새로 만듦: [email protected] AY52$ Application ID: MJFF-019845 (MC1 PET)

Uncertain Spans

locationtranscriptionuncertainty
Innovative Medicines / Co-MR.eu URLhttps://co-mr.eu/aria.eu/projects-results/project-factsheets/eubopenURL reads as written and may be a partial / OCR artefact; preserved verbatim.

그래프 뷰

백링크